<DOC>
	<DOCNO>NCT01588171</DOCNO>
	<brief_summary>The use new generation low molecular weight heparin ( Bemiparin ) well know LMWH ( Enoxaparin ) Caesarean section vaginal delivery risky group patient venous thrombosis .</brief_summary>
	<brief_title>Comparison 2 Low Molecular Weight Heparin Thromboprophylaxis Postpartum</brief_title>
	<detailed_description>Venous thromboembolism ( VTE ) lead cause maternal mortality morbidity develop develop world . Pulmonary embolism deep vein thrombosis two component single disease call deep vein thrombosis ( DVT ) . Pregnancy associate average 5 10 fold increase risk VTE compare non-pregnant woman . The high incidence occur post partum period . There many research do broad effect LMWH decrease incidence VTE Caesarean section use two LMWH ( Enoxaparin Bemiparin ) alone one research compare alone together control group . Also accord knowledge publish literature thromboprophylaxis vaginal delivery</detailed_description>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Presence risk factor venous thromboembolism Any parity Mode delivery : vaginal , Emergency Elective Caesarean section No contraindication Heparin Active antenatal postpartum vaginal bleeding . Placenta previa Thrombocytopenia Sever renal liver disease Uncontrolled sever hypertension Any patient already Heparin pregnancy</criteria>
	<gender>Female</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>48 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Deep vein thrombosis</keyword>
	<keyword>Pulmonary embolism</keyword>
	<keyword>Low molecular weight heparin</keyword>
	<keyword>Enoxaparin</keyword>
	<keyword>Bemiparin</keyword>
</DOC>